JP2002518016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002518016A5 JP2002518016A5 JP2000554860A JP2000554860A JP2002518016A5 JP 2002518016 A5 JP2002518016 A5 JP 2002518016A5 JP 2000554860 A JP2000554860 A JP 2000554860A JP 2000554860 A JP2000554860 A JP 2000554860A JP 2002518016 A5 JP2002518016 A5 JP 2002518016A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- kinase polypeptide
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 description 87
- 108090000765 processed proteins & peptides Proteins 0.000 description 87
- 102000004196 processed proteins & peptides Human genes 0.000 description 87
- 125000003275 alpha amino acid group Chemical group 0.000 description 54
- 238000000034 method Methods 0.000 description 54
- 108091000080 Phosphotransferase Proteins 0.000 description 53
- 102000020233 phosphotransferase Human genes 0.000 description 53
- 108020004707 nucleic acids Proteins 0.000 description 45
- 102000039446 nucleic acids Human genes 0.000 description 45
- 239000002773 nucleotide Substances 0.000 description 45
- 125000003729 nucleotide group Chemical group 0.000 description 45
- 150000007523 nucleic acids Chemical class 0.000 description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
- 239000000126 substance Substances 0.000 description 30
- 201000010099 disease Diseases 0.000 description 28
- 239000000523 sample Substances 0.000 description 27
- 241000124008 Mammalia Species 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 15
- 101000896657 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 Proteins 0.000 description 14
- -1 Amino Chemical group 0.000 description 13
- 210000004899 c-terminal region Anatomy 0.000 description 12
- 101000601467 Homo sapiens Serine/threonine-protein kinase Nek5 Proteins 0.000 description 9
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 208000026278 immune system disease Diseases 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000002853 nucleic acid probe Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- LYOKOJQBUZRTMX-UHFFFAOYSA-N 1,3-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxy]-2,2-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxymethyl]propane Chemical group FC(F)(F)C(C(F)(F)F)(C(F)(F)F)OCC(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F LYOKOJQBUZRTMX-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 201000007455 central nervous system cancer Diseases 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 102100021691 Mitotic checkpoint serine/threonine-protein kinase BUB1 Human genes 0.000 description 1
- 101150076596 bub-1 gene Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8952098P | 1998-06-16 | 1998-06-16 | |
| US60/089,520 | 1998-06-16 | ||
| US9826598P | 1998-08-28 | 1998-08-28 | |
| US60/098,265 | 1998-08-28 | ||
| PCT/US1999/013533 WO1999066051A2 (en) | 1998-06-16 | 1999-06-15 | Nek-related and bub1-related protein kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002518016A JP2002518016A (ja) | 2002-06-25 |
| JP2002518016A5 true JP2002518016A5 (enExample) | 2006-07-20 |
Family
ID=26780662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000554860A Withdrawn JP2002518016A (ja) | 1998-06-16 | 1999-06-15 | Ｎｅｋ関連及びｂｕｂ１関連プロテインキナーゼ |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1088079A2 (enExample) |
| JP (1) | JP2002518016A (enExample) |
| AU (1) | AU4686299A (enExample) |
| CA (1) | CA2331889A1 (enExample) |
| WO (1) | WO1999066051A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6183962B1 (en) * | 1998-09-09 | 2001-02-06 | Millennium Pharmaceuticals, Inc. | Protein kinase molecules and uses therefor |
| DE10011530A1 (de) * | 2000-03-13 | 2001-09-27 | Robert Elez | Hochwirksame Antisense-Oligodesoxynucleotide gegen Polio-like Kinasel |
| AU2001266954A1 (en) * | 2000-06-15 | 2001-12-24 | Millennium Pharmaceuticals, Inc. | 53070, a novel human protein kinase family member and uses thereof |
| AU2001273350A1 (en) * | 2000-07-11 | 2002-01-21 | Deltagen, Inc. | Transgenic mice containing targeted kinase gene disruptions |
| AU2002214576A1 (en) * | 2000-10-13 | 2002-04-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Genes related to development of refractory prostate cancer |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US20040097441A1 (en) * | 2002-11-16 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of NIMA-related kinase 6 expression |
| EP1554578A2 (en) * | 2002-06-11 | 2005-07-20 | The General Hospital Corporation | Identification of inhibitors of mitosis |
| CA2907730A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted indazoles |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863780A (en) * | 1996-09-12 | 1999-01-26 | Incyte Pharmaceuticals, Inc. | Human Protein Kinases |
| AU7828698A (en) * | 1997-06-11 | 1998-12-30 | Chiron Corporation | Detection of loss of the wild-type (hu)bub1 gene |
| AU1614099A (en) * | 1997-12-01 | 1999-06-16 | Fox Chase Cancer Center | Novel genes encoding proteins involved in mitotic checkpoint control and methodsof use thereof |
| WO1999047638A2 (en) * | 1998-03-16 | 1999-09-23 | The Johns Hopkins University School Of Medicine | Mutations in mitotic check point genes and methods of diagnosis |
| US5928874A (en) * | 1998-03-27 | 1999-07-27 | Incyte Pharmaceuticals, Inc. | Nek1-related protein kinase |
| CN1158386C (zh) * | 1998-04-29 | 2004-07-21 | 吉尼西斯研究及发展有限公司 | 从皮肤细胞中分离的多核苷酸及其使用方法 |
| JP2002524046A (ja) * | 1998-08-04 | 2002-08-06 | イミュネックス・コーポレーション | キナーゼ作用を有するポリペプチドをコードするマウスｄｎａ分子 |
-
1999
- 1999-06-15 AU AU46862/99A patent/AU4686299A/en not_active Abandoned
- 1999-06-15 WO PCT/US1999/013533 patent/WO1999066051A2/en not_active Ceased
- 1999-06-15 CA CA002331889A patent/CA2331889A1/en not_active Abandoned
- 1999-06-15 EP EP99930298A patent/EP1088079A2/en not_active Ceased
- 1999-06-15 JP JP2000554860A patent/JP2002518016A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003501038A5 (enExample) | ||
| CA2443617C (en) | Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions | |
| US6905844B2 (en) | Human cervical cancer 2 protooncogene and protein encoded therein | |
| CA2266325A1 (en) | A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof | |
| JP2002522009A5 (enExample) | ||
| KR100331363B1 (ko) | 사이클린복합체재배열및그것과관련된용도 | |
| US20090035819A1 (en) | CA125 gene and its use for diagnostic and therapeutic interventions | |
| ITMI992519A1 (it) | Proteine (iip) che interagiscono con il recettore igf-1 geni che le codificano e loro impiego | |
| HUP9800784A2 (hu) | Angiosztatin-fragmensek, aggregált angiosztatin és alkalmazásuk | |
| KR19990087802A (ko) | 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법 | |
| CA2395729A1 (en) | NUCLEIC ACIDS, PROTEINS AND ANTIBODIES | |
| JP2004501608A5 (enExample) | ||
| FR14C0061I2 (fr) | Sequences de circovirus associe a la maladie de l'amaigrissement du porcelet (map) | |
| PL1697507T3 (pl) | Zastosowanie białek i peptydów kodowanych przez genom nowego szczepu koronawirusa związanego z SARS | |
| JP2003519463A (ja) | ＴＣＬ−１ｂ遺伝子、蛋白質、それらに関連した方法およびそれらに関連する物質 | |
| JP2007506417A5 (enExample) | ||
| JP2005512515A5 (enExample) | ||
| WO2000062809A1 (en) | Proliferation inhibitor for androgen-independent tumor | |
| JP2004506420A5 (enExample) | ||
| JP2002517244A (ja) | 前立腺癌において示差的に調節される遺伝子および遺伝子発現産物 | |
| CN116322750A (zh) | 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法 | |
| CA2104964A1 (en) | Cancer diagnosis and therapy with tumor suppressor genes | |
| JP2002518016A5 (enExample) | ||
| Struss et al. | PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme | |
| EP2340845B1 (en) | Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions |